Characterization of the TLR9-Activating Potential of LNA-Modified Antisense Oligonucleotides

Overview of attention for article published in Nucleic Acid Therapeutics, July 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#32 of 874)
High Attention Score compared to outputs of the same age (96th percentile)

Mentioned by

news: 6 news outlets

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 6 news stories from 6 outlets.

Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs

ValueSpectrum, 22 Jul 2024

EQS-News: Secarna Pharmaceuticals GmbH

EQS-News: Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs

Bayerische Börse, 22 Jul 2024

EQS-News: Secarna Pharmaceuticals GmbH

EQS-News: Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies…

börsenNEWS.de, 22 Jul 2024

EQS-News: Secarna Pharmaceuticals GmbH

News story from Finanz Nachrichten on Monday 22 July 2024

Finanz Nachrichten, 22 Jul 2024

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 2 additional news stories.